Seeking Alpha

More on Hospira (HSP) Q3: swings to net profit of $1.2M from loss of $88.9M last year. Strong...

More on Hospira (HSP) Q3: swings to net profit of $1.2M from loss of $88.9M last year. Strong U.S. and EMEA sales of several of its specialty injectable pharmaceutical products offset the impact to supply of the Hospira's quality-improvement efforts. Continues to expect 2012 net sales of -1% to +2%, excluding the impact of forex. Forecasts adjusted EPS of $2, in line. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)